PRECIGEN, INC. Intangible Assets, Net (Excluding Goodwill)
PRECIGEN, INC. (PGEN) had Intangible Assets, Net (Excluding Goodwill) of $2.54 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization
us-gaap:IntangibleAssetsNetExcludingGoodwill · last filed 2026-08-04
- 2026-06-30: Intangible Assets, Net (Excluding Goodwill) $2.54M.
- 2026-03-31: Intangible Assets, Net (Excluding Goodwill) $2.86M.
- 2025-12-31: Intangible Assets, Net (Excluding Goodwill) $3.18M.
- 2025-09-30: Intangible Assets, Net (Excluding Goodwill) $3.50M.
| Period end | Intangible Assets, Net (Excluding Goodwill) | Intangible Assets, Net (Excluding Goodwill) as first filed |
|---|---|---|
| 2026-06-30 | $2.54M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $2.86M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $3.18M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $3.50M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $3.82M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $4.14M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $4.46M 10-K · filed 2026-03-25 | |
| 2024-09-30 | $4.77M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $5.09M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $38.72M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $40.70M 10-K · filed 2025-03-19 | |
| 2023-09-30 | $40.43M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $42.66M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $43.85M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $44.45M 10-K · filed 2024-03-19 | |
| 2022-09-30 | $42.42M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $45.93M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $51.43M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $52.29M 10-K · filed 2023-03-06 | $54.12M 10-K · filed 2022-03-01 |
| 2021-09-30 | $56.91M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $59.94M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $61.23M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $65.40M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $65.02M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $64.76M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $65.49M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $68.35M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $107.14M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $112.53M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $125.87M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $88.96M 10-K · filed 2020-03-02 | $129.29M 10-K · filed 2019-03-01 |
| 2018-09-30 | $213.24M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $218.84M 10-Q · filed 2018-08-13 | |
| 2018-03-31 | $231.88M 10-Q/A · filed 2018-08-13 | |
| 2017-12-31 | $232.88M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $240.90M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $240.36M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $223.07M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $225.62M 10-K · filed 2018-03-01 | |
| 2016-09-30 | $238.58M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $244.31M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $255.46M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $247.53M 10-K · filed 2017-03-01 | |
| 2015-09-30 | $256.28M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $162.23M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $129.31M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $65.95M 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |